Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06411821 · ClinicalTrials.gov registry record · Phase 2
Ulixertinib in People With Histiocytic Neoplasms
A Phase 2 study of Histiocytic Neoplasms, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 8
- Study locations
NCT06411821 is a Phase 2 study of Histiocytic Neoplasms that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 38 participants. The trial reports 8 study locations across 3 states.
The verdict
NCT06411821, a Phase 2 study of Histiocytic Neoplasms, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 8
- Study locations
Study Summary
The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.
Conditions Studied
Interventions
- DRUG Ulixertinib
Study Locations (8)
New York
- Memorial Sloan Kettering Suffolk-Commack (Consent Only) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Consent Only) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Consent Only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Consent Only) - Montvale
Minnesota
- Mayo Clinic (Data Collection Only) - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-05-07 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06411821
The ClinicalTrials.gov registry entry for NCT06411821 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Histiocytic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Ulixertinib is the first listed.
NCT06411821 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06411821 about?
NCT06411821 is a clinical study titled "Ulixertinib in People With Histiocytic Neoplasms". The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.
What is the current status of trial NCT06411821?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2024-05-07. Estimated completion is 2027-05.
What conditions does trial NCT06411821 study?
This clinical trial studies the following conditions: Histiocytic Neoplasms.
What interventions are being tested in trial NCT06411821?
The interventions under investigation include: Ulixertinib (DRUG).
Who is sponsoring clinical trial NCT06411821?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06411821 being conducted?
This trial has 8 study locations across Minnesota, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Histiocytic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.